June 9th 2024
Additionally, the 48-month overall survival rate was higher with nivolumab/cabozantinib vs sunitinib in the phase 3 CheckMate 9ER trial.
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Managing Immune-Related Toxicities with Frontline RCC Therapies
March 12th 2024Expert panelists discuss the importance of rapid improvement within 24-72 hours with steroids for managing unpredictable immune-related toxicities that can occur with frontline IO-IO or IO-TKI regimens for patients with RCC.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.
Apalutamide/AAP Improves Outcomes Without Negative HRQOL Impact in Prostate Cancer
January 26th 2024Six months of intensified androgen deprivation therapy plus next-generation anti-androgens may be an attractive option for those with prostate cancer and rising prostate specific antigen levels following prostatectomy.
Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma
Francisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.